Authors: Jun Dong Guanghua Zhou Dongfang Tang Yanming Chen Baoqian Cui Xingliang Dai Jinshi Zhang Qing Lan Qiang Huang
Publish Date: 2012/07/24
Volume: 138, Issue: 12, Pages: 2079-2084
Abstract
Currently treatment of malignant gliomas with temozolomide in addition to surgical resection and radiotherapy remains the foundation of glioma therapy In an effort to develop new therapeutic choices to treat malignant gliomas we have designed slowreleasing microspheres that deliver temozolomide PTMZ The local continuous release of temozolomide at the intracranial tumor site may overcome many obstacles associated with systemic delivery which will help to further improving the therapeutic effects against malignant gliomasSlowreleasing microspheres containing 10 temozolomide were prepared the antitumor efficacy in vitro was evaluated with MTT assay and the therapeutic efficacy in vivo against gliomas was assessed in human glioma SGH44 nude mice sc and orthotopic xenograft modelsA single local injection of PTMZ led to significant reduction both in sc and orthotopic human SHG44 glioma xenografts PTMZ BCNU and TMZ had significant antiglioma effect P 001 their IC50 value was all less than 10 μg/ml Tumor inhibition ratio of PTMZ BCNU and TMZ in vivo was higher than empty microspheres P0 P 001 PTMZ and BCNU showed higher antitumor efficacy than TMZ P 005Our present results suggest that local delivery of slowreleasing temozolomide microspheres is effective for malignant gliomas PTMZ retained good antitumor activity and had better therapeutic effect against glioma both in vitro and in vivo which provide a new choice for future clinical interstitial chemotherapyThis study was supported by National Natural Science Foundation of China No 81071766 and Natural Science Foundation of Jiangsu Province China BK2010227 We thank Dr Hailong Yang Chemical Medicine Laboratory Tianjin Tasly Institute Tianjin 300402 China for kindly offering TMZ and slowreleasing temozolomide microspheres
Keywords: